Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human embryonic stem cell-derived mesenchymal stem cells (hES-MSCs) are a specialized population of mesenchymal stem cells generated through the directed differentiation of pluripotent human embryonic stem cells. Unlike adult MSCs derived from bone marrow or adipose tissue, hES-MSCs offer a more scalable and highly standardized "off-the-shelf" therapeutic source with superior proliferative capacity and consistent immunomodulatory properties. These cells function primarily through the secretion of anti-inflammatory cytokines and trophic factors, which modulate T-cell responses and promote tissue repair. They are being investigated for a variety of conditions, including autoimmune diseases like multiple sclerosis and systemic lupus erythematosus, as well as regenerative applications such as primary ovarian insufficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human embryonic stem cell-derived mesenchymal stem cells.